EVCYT
A stranger
LIFESAVER: Living Impact on Fetal Evolution Shelter Analyze Validate Empower Regulations
EVERCYTE GMBH
participó en un
H2020
H2020-LC-GD-2020
In Europe about 75% of all neonatal deaths and 60% of all infant deaths occur in infants born preterm, and worldwide 450 neonatal deaths occ...
2021-09-28 - 2025-10-31 | financed
2021-09-28 - 2025-10-31 | financed
in3: An integrated interdisciplinary approach to animal free chemical and nanomaterial safety assessment
EVERCYTE GMBH
participó en un
H2020
H2020-MSCA-ITN-2016
All chemicals whether they are drugs, cosmetics, agrochemicals or others need to be tested for their safety to man and the environment. The...
2016-08-31 - 2021-06-30 | financed
2016-08-31 - 2021-06-30 | financed
eCHO Systems: Enhancing CHO by Mammalian Systems Biotechnology eCHO systems
EVERCYTE GMBH
participó en un
H2020
H2020-MSCA-ITN-2014
Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms...
2014-12-05 - 2018-12-31 | financed
2014-12-05 - 2018-12-31 | financed
FRAILOMIC: Utility of omic based biomarkers in characterizing older individuals at risk for frailty its progre...
EVERCYTE GMBH
participó en un
FP7
The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disabi...
financed
financed
NANOII: Nanoscopically guided induction and expansion of regulatory hematopoietic cells to treat autoimmune...
EVERCYTE GMBH
participó en un
FP7
We propose a multidisciplinary program, focusing on the development of novel approaches for directing the differentiation, proliferation and...
financed
financed
SYBIL: Systems biology for the functional validation of genetic determinants of skeletal diseases
EVERCYTE GMBH
participó en un
FP7
"The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the a...
financed
financed
NANOCARD: Nanopatterned scaffolds for active myocardial implants
EVERCYTE GMBH
participó en un
FP7
Cell therapy and tissue engineering are emerging as novel therapeutic paradigms for myocardial repair. The rationale behind the cell replace...
financed
financed
* No data from the current company are not available.